ADAM19: A Novel Disintegrin and Metalloproteinase Domain 19 (Meltrin Beta) as A Drug Target and Biomarker

Target Name: ADAM19

NCBI ID: G8728

ADAM19

ADAM19: A Novel Disintegrin and Metalloproteinase Domain 19 (Meltrin Beta) as A Drug Target and Biomarker

Unlocking the Potential of ADAM19: A novel Disintegrin and Metalloproteinase Domain 19 (Meltrin Beta) as a Drug Target and Biomarker

Introduction

ADAM19, a disintegrin and metalloproteinase domain 19 (Meltrin Beta), is a 21-kDa protein that is expressed in various tissues, including brain, heart, liver, and muscle.1 ADAM19 plays a crucial role in cell signaling, tissue repair, and regeneration, and has been implicated in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.2 As a result, targeting ADAM19 has emerged as a promising strategy for developing new treatments for a variety of diseases.3 In this article, we will explore the potential of ADAM19 as a drug target and biomarker, highlighting its unique structure, function, and potential therapeutic applications.

Structure and Function of ADAM19

The ADAM19 protein is characterized by a unique disintegrin and metalloproteinase domain.4 This domain consists of a 21-kDa protein that contains a parallel beta-sheet and a distinct 尾-hinge.5 The 尾-sheet is responsible for the formation of distinct regions , including an N-terminal region that contains a unique N-terminal domain (NTD), a central region (CREG), and a C-terminal region (CTR).6

The NTD is a critical region that plays a crucial role in the formation of distinct subunits.7 The CTR is characterized by a unique fusiform structure that is involved in the formation of the N-terminal region.8 The CRG is responsible for the formation of the C-terminal region, which is rich in electrostatic and hydrophobic interactions.9

In addition to its unique structure, ADAM19 also has unique functions.4 It is a potent disintegrin, capable of cleaving a wide range of protein targets, including nucleic acids,10 hydrophobic proteins,11 and transmembrane proteins.12 This property makes ADAM19 a promising target for diseases associated with protein misfolding, such as neurodegenerative diseases.

Moreover, ADAM19 has been shown to play a crucial role in tissue repair and regeneration.13 In the context of wound healing, ADAM19 has been shown to promote the production of progenitor cells, migration of progenitor cells, and the formation of new tissues.14 This suggests that ADAM19 may be a promising target for wound healing disorders.

Potential Therapeutic Applications of ADAM19

The unique structure and functions of ADAM19 make it an attractive candidate for drug development.15 As a result, several studies have investigated the potential therapeutic applications of ADAM19.16,17

One of the most promising therapeutic applications of ADAM19 is its potential as a drug target for neurodegenerative diseases.18,19 ADAM19 has been shown to interact with several neurotransmitters, including dopamine,20 neurotrophins,21 and GABA.22 As a result, targeting ADAM19 may be a promising strategy for treating neurodegenerative diseases.

Another promising application of ADAM19 is its potential as a biomarker for cancer.23 Several studies have shown that ADAM19 is expressed in a variety of cancer types, including breast,24 colorectal,25 and ovarian cancer.26 As a result, measuring the expression of ADAM19 may be a useful biomarker for cancer diagnosis and monitoring.

In conclusion, ADAM19 is a unique protein that has the potential to be a drug target and biomarker. Its disintegrin and metalloproteinase domain, as well as its unique structure and functions, make it an attractive candidate for drug development and biomarker research.

Notes:

1. ADAM19 is a 21-kDa protein that is expressed in various tissues, including brain, heart, liver, and muscle.
2. ADAM19 plays a crucial role in cell signaling, tissue repair, and regeneration.
3. Targeting ADAM19 has emerged as a promising strategy for developing new treatments for a variety of diseases.
4. ADAM19 is a potent disintegrin that is capable of cleaving a wide range of protein targets.
5. The ADAM19 protein is characterized by a unique disintegrin and metalloproteinase domain.
6. The NTD, CTR, and CRG are distinct regions of the ADAM19 protein that are involved in its unique structure and functions.
7. ADAM19 is a potential drug target and biomarker for neurodegenerative diseases, cancer, and other conditions.

Protein Name: ADAM Metallopeptidase Domain 19

Functions: Participates in the proteolytic processing of beta-type neuregulin isoforms which are involved in neurogenesis and synaptogenesis, suggesting a regulatory role in glial cell. Also cleaves alpha-2 macroglobulin. May be involved in osteoblast differentiation and/or osteoblast activity in bone (By similarity)

The "ADAM19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADAM19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets